{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:26:04Z","timestamp":1792070764937,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejca.2012.08.003","type":"journal-article","created":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T15:49:28Z","timestamp":1346514568000},"page":"329-335","source":"Crossref","is-referenced-by-count":106,"title":["Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study"],"prefix":"10.1016","volume":"49","author":[{"given":"Thomas","family":"Walter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"McKeever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hedley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika K.","family":"Krzyzanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.08.003_b0005","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","article-title":"Biliary tract cancers","volume":"341","author":"de Groen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.08.003_b0010","series-title":"AJCC cancer staging handbook","first-page":"718","article-title":"Perihilar bile ducts","author":"Edge","year":"2010"},{"key":"10.1016\/j.ejca.2012.08.003_b0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2012.08.003_b0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.9-1-43","article-title":"Diagnosis and treatment of cholangiocarcinoma","volume":"9","author":"Anderson","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2012.08.003_b0025","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.08.003_b0040","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.4520","article-title":"A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial","volume":"27","author":"Malka","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/MEG.0b013e3283396dde","article-title":"Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma","volume":"22","author":"Cassier","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2012.08.003_b0050","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s10637-010-9485-4","article-title":"Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer","volume":"29","author":"Sasaki","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2012.08.003_b0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","article-title":"Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine","volume":"30","author":"Sasaki","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2012.08.003_b0060","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10637-010-9417-3","article-title":"Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness","volume":"29","author":"Oh","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2012.08.003_b0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000055230","article-title":"Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases","volume":"25","author":"Stemmler","year":"2002","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2012.08.003_b0070","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","article-title":"Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial","volume":"23","author":"Knox","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0075","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/cncr.22902","article-title":"Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer","volume":"110","author":"Riechelmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.08.003_b0080","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andre","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2012.08.003_b0085","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andre","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0090","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00280-011-1657-1","article-title":"A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202","volume":"68","author":"Iqbal","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2012.08.003_b0095","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2012.08.003_b0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.20753","article-title":"Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial","volume":"103","author":"Alberts","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.08.003_b0105","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/cncr.21591","article-title":"Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma","volume":"104","author":"Cho","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.08.003_b0110","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","article-title":"A phase II study of gemcitabine in gallbladder carcinoma","volume":"12","author":"Gallardo","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0115","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1245\/s10434-007-9539-9","article-title":"A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study","volume":"14","author":"Iyer","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/annonc\/mdi046","article-title":"Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma","volume":"16","author":"Thongprasert","year":"2005","journal-title":"Ann Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.ejca.2012.08.003_b0125","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/annonc\/mdl955","article-title":"Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers","volume":"17","author":"Verderame","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0130","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","article-title":"Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group","volume":"47","author":"Pelzer","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.08.003_b0135","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/COC.0b013e31818c08ff","article-title":"Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer","volume":"32","author":"Lee","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000331065","article-title":"Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study","volume":"34","author":"Roth","year":"2011","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2012.08.003_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4508","article-title":"A randomized trial in patients with gemcitabine refractory pancreatic cancer. Filan results of the CONKO003","volume":"26","author":"Pelzer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0150","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.e14500","article-title":"Efficacy and safety of RAD001 I advanced biliary tract cancer patients progressing after first-line chemotherapy: a phase II study","volume":"28","author":"Buzzoni","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0155","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.08.003_b0160","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2010.28.4075","article-title":"Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study","volume":"28","author":"Lubner","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912006284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912006284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:09:23Z","timestamp":1643332163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912006284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0959804912006284"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.08.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}